Explore the Potential with AI-Driven Innovation
This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.
The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by our partner Reaxense.
The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.
Our top-notch dedicated system is used to design specialised libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our strategy employs molecular simulations to explore an extensive range of proteins, capturing their dynamics both individually and within complexes with other proteins. Through ensemble virtual screening, we address proteins' conformational mobility, uncovering key binding sites at both functional regions and remote allosteric locations. This comprehensive investigation ensures a thorough assessment of all potential mechanisms of action, with the goal of discovering innovative therapeutic targets and lead molecules across across diverse biological functions.
Our library is unique due to several crucial aspects:
partner
Reaxense
upacc
P29016
UPID:
CD1B_HUMAN
Alternative names:
-
Alternative UPACC:
P29016; Q5TDK9; Q5TDL0; Q9UMM2
Background:
T-cell surface glycoprotein CD1b plays a pivotal role in the immune system by presenting lipid and glycolipid antigens to T-cell receptors on natural killer T-cells. This antigen-presenting protein's ability to bind both self and non-self molecules is crucial for the activation and regulation of natural killer T-cells.
Therapeutic significance:
Understanding the role of T-cell surface glycoprotein CD1b could open doors to potential therapeutic strategies. Its unique function in the immune response highlights its potential as a target for immunotherapy treatments, aiming to harness the body's own defenses to fight diseases.